Loading patent…
AssigneeTao Health Life Pharma Co., Ltd.
InventorMinako Hoshi
Estimating the term…
In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na+/K+-ATPase α3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na+/K+-ATPase α3, and the like.
A method for inhibiting protein-protein interaction between amylospheroid and Na+/K+-ATPase α3, consisting of causing at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody to interact with ASPD or NAKα3, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X1X2NW (SEQ ID NO:8) or X2NW (SEQ ID NO:49) at the N-terminal, wherein X1 is arginine, histidine, or lysine, and X2 is hydrophobic amino acid residue or glycine.
A method for suppressing death of a mature neuron induced by amylospheroid, comprising inhibiting protein-protein interaction between the amylospheroid and Na+/K+-ATPase α3 by administering to a subject in need thereof at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X1X2NW (SEQ ID NO:8) or X2NW (SEQ ID NO:49) at the N-terminal, wherein X1 is arginine, histidine, or lysine, and X2 is hydrophobic amino acid residue or glycine.
A method for preventing, ameliorating, and/or treating Alzheimer's disease and/or dementia with Lewy bodies, comprising suppressing death of a mature neuron induced by amylospheroid by inhibiting protein-protein interaction between the amylospheroid and Na+/K+-ATPase α3 by administering to a subject in need thereof at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X1X2NW (SEQ ID NO:
Dependencies are inferred from the claim text.